A Phase I/II Study of Vorinostat in Combination With Low Dose Ara-C for Patients With Intermediate-2 or High Risk Myelodysplastic Syndromes.

Trial Profile

A Phase I/II Study of Vorinostat in Combination With Low Dose Ara-C for Patients With Intermediate-2 or High Risk Myelodysplastic Syndromes.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 May 2014

At a glance

  • Drugs Vorinostat (Primary) ; Cytarabine
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Nov 2011 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
    • 25 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Nov 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top